BiotechTube
Home/Aardvark Therapeutics/Roy D. Baynes
RD

Roy D. Baynes

Independent Director

Aardvark Therapeutics

Therapeutic Areas

Metabolic DiseasesRare DiseasesObesity

Aardvark Therapeutics Pipeline

DrugIndicationPhase
ARD-101Prader-Willi Syndrome (Hyperphagia)Phase 3 (Planned)

Leadership Team at Aardvark Therapeutics

TL
Tien Lee
Chief Executive Officer
SE
Susan E. Graf
Independent Director
View full Aardvark Therapeutics profile